San Francisco, 18 September 2018: The global systemic lupus erythematosus market size is expected to
reach USD 3.08 billion by 2025, according to a new report by Grand View
Research, Inc., exhibiting a CAGR of 7.0% during the forecast
period.Introduction of new biological therapies, which will add to treatment
alternatives and medication costs, in the development pipeline is estimated to
fuel revenue generation of the market. Certain new promising drugs that are
currently in Phase III trials are anticipated to augment the market as these
drugs may target the lupus nephritis patient subset with few effective
alternatives and significant unmet needs to be met. This factor is likely to have
a strong impact on the market as nearly 50.0% of SLE patients suffer with lupus
nephritis.
Use
of approved biologic, Benlysta, through clinical studies, has revealed drastic
improvements and substantial decrease in consumption of anti-inflammatory glucocorticoids
in moderate SLE cases. GSK’s current initiatives center on further increasing
opportunities for Benlysta. The company is conducting indication expansion
clinical trials, combination therapy studies with rituximab, and new product
development, to widen opportunities for its therapy. In this direction, recent
launch of Benlysta’s subcutaneous formulation in several countries is expected
to boost the SLE market over the forecast period.
Access
Research Report of SLE Market @ www.grandviewresearch.com/industry-analysis/systemic-lupus-erythematosus-sle-market
Further key findings
from the study suggest:
· North
America was the major contributor for the SLE market revenue in 2017 and is
anticipated to rise at a CAGR of 8.1% during the forecast period. This is due
to availability of reimbursement and better healthcare infrastructure and
accessibility to biologics.
· Europe
was ranked as the second largest regional market in the SLE market in 2017 and
is expected to register a CAGR of 5.5% over the forecast period
· Immunosuppressants
held the largest share in the market in 2017 due to their low cost and high accessibility,
whereas the biologics segment is projected to post the highest CAGR during the
same period
· In
2017, the oral segment held the dominant share of over 54.0% in the market,
followed by the intravenous segment that requires trained medical personnel for
administration. Over the forecast years, the latter is poised to expand at a
CAGR of 10.4%
· Key
players in this space include GlaxoSmithKline, Roche, Pfizer, Novartis, Bayer,
and Sanofi. By 2025, other companies such as ImmuPharma, Aurinia Pharmaceuticals,
and Astra Zeneca are anticipated to enter the SLE market.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand
View Research has segmented the global systemic lupus erythematosus market by
drug class, route of administration, and region:
Systemic Lupus Erythematosus Drug Classes
Outlook (Revenue, USD Million, 2014 - 2025)
·
NSAIDs
·
Corticosteroids
·
Antimalarials
·
Immunosuppressants
·
Biologics
Systemic Lupus Erythematosus Route of
Administration Outlook (Revenue, USD Million, 2014 - 2025)
·
Oral
·
Intravenous
·
Subcutaneous
Systemic Lupus Erythematosus Regional
Outlook (Revenue, USD Million, 2014 - 2025)
·
North
America
o U.S.
o Canada
·
Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Greece
o Sweden
o Norway
o Poland
o RoE
·
Asia
Pacific
o Japan
o China
o Hong Kong
o Taiwan
o South Korea
o New Zealand
o Australia
o India
o Malaysia
o Singapore
·
Latin
America
o Brazil
o Mexico
o Argentina
·
MEA
o Turkey
o Saudi Arabia
o Kuwait
o Israel
o
South Africa
Access Press Release of SLE Market@ www.grandviewresearch.com/press-release/global-systemic-lupus-erythematosus-sle-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports, and consulting services. To help
clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment